BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 33467674)

  • 1. Clinical and Molecular Insights in Erythropoiesis Regulation of Signal Transduction Pathways in Myelodysplastic Syndromes and β-Thalassemia.
    Parisi S; Finelli C; Fazio A; De Stefano A; Mongiorgi S; Ratti S; Cappellini A; Billi AM; Cocco L; Follo MY; Manzoli L
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis.
    Suragani RN; Cadena SM; Cawley SM; Sako D; Mitchell D; Li R; Davies MV; Alexander MJ; Devine M; Loveday KS; Underwood KW; Grinberg AV; Quisel JD; Chopra R; Pearsall RS; Seehra J; Kumar R
    Nat Med; 2014 Apr; 20(4):408-14. PubMed ID: 24658078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transforming growth factor (TGF)-β pathway as a therapeutic target in lower risk myelodysplastic syndromes.
    Bewersdorf JP; Zeidan AM
    Leukemia; 2019 Jun; 33(6):1303-1312. PubMed ID: 30962581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in MDS/AML and inositide signalling.
    De Stefano A; Marvi MV; Fazio A; McCubrey JA; Suh PG; Ratti S; Ramazzotti G; Manzoli L; Cocco L; Follo MY
    Adv Biol Regul; 2023 Jan; 87():100955. PubMed ID: 36706610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematopoietic cell kinase (HCK) is a potential therapeutic target for dysplastic and leukemic cells due to integration of erythropoietin/PI3K pathway and regulation of erythropoiesis: HCK in erythropoietin/PI3K pathway.
    Roversi FM; Pericole FV; Machado-Neto JA; da Silva Santos Duarte A; Longhini AL; Corrocher FA; Palodetto B; Ferro KP; Rosa RG; Baratti MO; Verjovski-Almeida S; Traina F; Molinari A; Botta M; Saad ST
    Biochim Biophys Acta Mol Basis Dis; 2017 Feb; 1863(2):450-461. PubMed ID: 27840303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia.
    Dussiot M; Maciel TT; Fricot A; Chartier C; Negre O; Veiga J; Grapton D; Paubelle E; Payen E; Beuzard Y; Leboulch P; Ribeil JA; Arlet JB; Coté F; Courtois G; Ginzburg YZ; Daniel TO; Chopra R; Sung V; Hermine O; Moura IC
    Nat Med; 2014 Apr; 20(4):398-407. PubMed ID: 24658077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Luspatercept in Myelodysplastic Syndromes: Who and When?
    Komrokji RS
    Hematol Oncol Clin North Am; 2020 Apr; 34(2):393-400. PubMed ID: 32089218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors.
    Mies A; Platzbecker U
    Semin Hematol; 2017 Jul; 54(3):141-146. PubMed ID: 28958287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
    Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
    J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients.
    Follo MY; Mongiorgi S; Clissa C; Paolini S; Martinelli G; Martelli AM; Fioravanti G; Manzoli L; Finelli C; Cocco L
    Leukemia; 2012 Dec; 26(12):2474-82. PubMed ID: 22596089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear Inositides and Inositide-Dependent Signaling Pathways in Myelodysplastic Syndromes.
    Xian J; Owusu Obeng E; Ratti S; Rusciano I; Marvi MV; Fazio A; De Stefano A; Mongiorgi S; Cappellini A; Ramazzotti G; Manzoli L; Cocco L; Follo MY
    Cells; 2020 Mar; 9(3):. PubMed ID: 32178280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ineffective erythropoiesis and its treatment.
    Cazzola M
    Blood; 2022 Apr; 139(16):2460-2470. PubMed ID: 34932791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes.
    Mongiorgi S; Finelli C; Yang YR; Clissa C; McCubrey JA; Billi AM; Manzoli L; Suh PG; Cocco L; Follo MY
    Expert Opin Ther Targets; 2016 Jun; 20(6):677-87. PubMed ID: 26610046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoiesis in lower-risk myelodysplastic syndromes and beta-thalassemia.
    Cappellini MD; Taher AT; Verma A; Shah F; Hermine O
    Blood Rev; 2023 May; 59():101039. PubMed ID: 36577601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis.
    Claessens YE; Bouscary D; Dupont JM; Picard F; Melle J; Gisselbrecht S; Lacombe C; Dreyfus F; Mayeux P; Fontenay-Roupie M
    Blood; 2002 Mar; 99(5):1594-601. PubMed ID: 11861273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spleen tyrosine kinase mediates the actions of EPO and GM-CSF and coordinates with TGF-β in erythropoiesis.
    Chang HC; Huang DY; Wu MS; Chu CL; Tzeng SJ; Lin WW
    Biochim Biophys Acta Mol Cell Res; 2017 Apr; 1864(4):687-696. PubMed ID: 28131718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia.
    Suragani RN; Cawley SM; Li R; Wallner S; Alexander MJ; Mulivor AW; Gardenghi S; Rivella S; Grinberg AV; Pearsall RS; Kumar R
    Blood; 2014 Jun; 123(25):3864-72. PubMed ID: 24795345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear inositide signaling in myelodysplastic syndromes.
    Follo MY; Mongiorgi S; Finelli C; Clissa C; Ramazzotti G; Fiume R; Faenza I; Manzoli L; Martelli AM; Cocco L
    J Cell Biochem; 2010 Apr; 109(6):1065-71. PubMed ID: 20058233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of luspatercept to treat ineffective erythropoiesis.
    Kubasch AS; Fenaux P; Platzbecker U
    Blood Adv; 2021 Mar; 5(5):1565-1575. PubMed ID: 33687432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Luspatercept in the treatment of lower-risk myelodysplastic syndromes.
    Chan O; Komrokji RS
    Future Oncol; 2021 Apr; 17(12):1473-1481. PubMed ID: 33511859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.